electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC
November 01, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only...
electroCore to Announce Third Quarter 2022 Financial Results on November 3
October 27, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury
October 20, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced data from an oral presentation at Neurocritical...
electroCore Provides Select Third Quarter 2022 Financial Guidance
October 14, 2022 16:01 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary...
Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases
October 11, 2022 08:30 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury
October 11, 2022 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing unique...
Odyssey Health, Inc. Provides Recap on Concussion Drug Development
October 06, 2022 08:30 ET
|
Odyssey Health, Inc
Las Vegas, Nevada, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Development Program
September 30, 2022 18:28 ET
|
Odyssey Health, Inc
Las Vegas Nevada, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., (the “Company” “Odyssey”) a company focused on developing a unique...
Insights on the Trauma Care Centers Global Market to 2030 - Increasing Number of Trauma Care Centers is Driving Growth
September 29, 2022 06:33 ET
|
Research and Markets
Dublin, Sept. 29, 2022 (GLOBE NEWSWIRE) -- The "Trauma Care Centers Market Size, Share & Trends Analysis Report by Facility Type (In-house, Standalone), by Trauma Type (Falls, Traffic-related...
electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents
September 21, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark...